Repatha vs Losartan: Head-to-Head Efficacy for Women's Heart Health

What Are These Two Drugs Actually Doing?

Repatha and losartan are not competitors in the clinical sense. They address separate drivers of cardiovascular disease. Repatha targets cholesterol. Losartan targets blood pressure. Many women with high cardiovascular risk are prescribed both simultaneously, not one instead of the other.

Understanding why each drug exists, and who it is designed for, will help you have a more specific conversation with your clinician.

How Repatha (Evolocumab) Works

Evolocumab is a monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, the liver clears more LDL from the bloodstream. The result is a dramatic and sustained LDL reduction, typically 50 to 60 percent below baseline when added to maximally tolerated statin therapy.

Repatha comes as a subcutaneous injection. The two approved dosing schedules are 140 mg every two weeks or 420 mg once monthly, both delivered via auto-injector or prefilled syringe.

How Losartan Works

Losartan blocks the angiotensin II type 1 receptor, preventing angiotensin II from constricting blood vessels and stimulating aldosterone release. The net effect is vasodilation, lower blood pressure, and reduced kidney filtration pressure. Standard dosing runs 25 to 100 mg daily, taken orally.

Beyond blood pressure, losartan carries a specific indication for reducing stroke risk in hypertensive patients with left ventricular hypertrophy and for slowing diabetic nephropathy progression in type 2 diabetes.

The Evidence Base: FOURIER vs LIFE

No randomized head-to-head trial has ever compared evolocumab directly against losartan. The two drugs have been studied in separate populations with different primary endpoints. Presenting the trials side by side requires intellectual honesty about what the data can and cannot tell you.

FOURIER (NEJM 2017): Evolocumab in Established ASCVD

The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) who were already on statin therapy. Participants were randomized to evolocumab or placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina) by a relative 15 percent (hazard ratio 0.85; 95% CI 0.79-0.92).

LDL dropped from a median of 92 mg/dL at baseline to 30 mg/dL in the evolocumab arm. That 59 mg/dL absolute reduction confirms the drug's potency at the cholesterol level.

Women made up approximately 24 percent of the FOURIER population, a proportion that limits sex-specific conclusions. Subgroup analyses suggested the relative risk reduction was directionally consistent in women, though the confidence intervals were wider given the smaller sample. This is an evidence gap you deserve to know about. The cardiovascular outcomes data in women on PCSK9 inhibitors is extrapolated from male-majority trials, not directly established in female-powered studies.

LIFE (Lancet 2002): Losartan in Hypertension with LVH

The LIFE trial enrolled 9,193 patients aged 55-80 with hypertension and electrocardiographic left ventricular hypertrophy (LVH). Participants were randomized to losartan-based or atenolol-based treatment. The losartan group achieved a 13 percent relative reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke (hazard ratio 0.87; 95% CI 0.77-0.98) despite similar blood pressure lowering in both arms.

Women represented about 54 percent of the LIFE cohort, making it one of the better-powered cardiovascular trials for female-specific signals. The stroke reduction was particularly pronounced: losartan reduced fatal or non-fatal stroke by 25 percent relative to atenolol, a finding that holds relevance for perimenopausal and postmenopausal women, whose stroke risk rises with age-related blood pressure increases.

What the Trial Comparison Actually Tells You

| Feature | FOURIER (Repatha) | LIFE (Losartan) | |---|---|---| | Primary problem treated | Elevated LDL / ASCVD | Hypertension with LVH | | Relative MACE reduction | 15% | 13% vs atenolol | | Women in trial | ~24% | ~54% | | Absolute LDL change | -59 mg/dL | Minimal | | Blood pressure effect | Modest (-1 to -2 mmHg) | Significant (-10 to -15 mmHg) | | Route | Subcutaneous injection | Oral tablet |

These trials are not measuring the same thing. A 15 percent MACE reduction in established ASCVD on top of statin therapy is not the same as a 13 percent reduction in a hypertensive population without necessarily having prior MI or stroke. Comparing the numbers directly would be misleading.

Sex-Specific Physiology: Why This Comparison Looks Different for Women

Women's cardiovascular risk profile is shaped by hormonal shifts across the lifespan in ways that affect both cholesterol and blood pressure trajectories. That biology changes how each drug fits into your care.

Cholesterol Across Female Life Stages

LDL cholesterol follows a predictable hormonal arc in women. During the reproductive years, estrogen upregulates hepatic LDL receptors, keeping LDL relatively lower than in age-matched men. At perimenopause, falling estrogen reduces receptor activity, and LDL rises sharply. A longitudinal analysis from the SWAN study found LDL increased by an average of 10.7 mg/dL in the two years surrounding the final menstrual period, a clinically meaningful jump that can tip a woman who was previously at moderate risk into high-risk territory.

This is the life stage where PCSK9 inhibition becomes most relevant for women who have familial hypercholesterolemia, statin intolerance, or established ASCVD with LDL that remains above goal on maximally tolerated statin therapy.

Blood Pressure Across Female Life Stages

Premenopausal women generally have lower blood pressure than men of the same age. That protection dissolves at menopause. The American Heart Association's 2021 scientific statement on cardiovascular disease in women documented that blood pressure rises more steeply in women after menopause than in men of comparable age, partly driven by estrogen loss reducing nitric oxide availability and increasing vascular stiffness.

Women with PCOS carry elevated blood pressure risk even in their twenties and thirties, independent of weight. Hypertension in PCOS is driven by insulin resistance, sympathetic overactivation, and renin-angiotensin-aldosterone system dysregulation. ARBs like losartan are a reasonable antihypertensive choice in PCOS precisely because the renin-angiotensin system is already upregulated, though no large trial has confirmed superior outcomes specifically in PCOS populations.

Menstrual Cycle Effects on Cardiovascular Parameters

Blood pressure fluctuates modestly across the cycle. Systolic pressure may be 2 to 5 mmHg lower in the late follicular phase relative to the luteal phase, driven by progesterone's natriuretic effect and estrogen's vasodilatory action. These variations are unlikely to change your losartan dose but matter if you are tracking blood pressure at home and seeing readings that seem inconsistent.

Cholesterol also shifts across the cycle. LDL is measurably higher in the luteal phase. If your clinician is monitoring LDL on Repatha, the timing of your lipid panel relative to your cycle can introduce noise. Standardizing the draw to the early follicular phase (days 2-5) reduces this variability.

Who This Is Right for (and Who It Is Not)

This framework is designed to help you and your clinician decide which drug belongs in your care plan, recognizing that some women need both.

Repatha Is Most Appropriate for You If:

• You have established ASCVD (prior MI, stroke, or peripheral artery disease) and LDL remains at or above 70 mg/dL despite maximally tolerated statin therapy
• You have heterozygous or homozygous familial hypercholesterolemia, diagnosed by clinical criteria or genetic testing
• You are statin-intolerant and have significantly elevated LDL with high baseline cardiovascular risk
• You are postmenopausal with a rapid post-transition LDL rise that statins have not fully controlled
• You can manage a subcutaneous injection every two weeks or monthly and your insurance or a manufacturer copay program covers the cost (list price exceeds $600 per month without coverage)

Repatha Is Not Appropriate If:

• Your primary cardiovascular risk driver is uncontrolled blood pressure, not elevated LDL
• You are pregnant, planning pregnancy in the near term, or breastfeeding (see pregnancy section below)
• Your LDL is already at goal on current therapy

Losartan Is Most Appropriate for You If:

• You have confirmed hypertension, defined as persistent blood pressure at or above 130/80 mmHg per 2023 ACC/AHA guidelines after lifestyle modification
• You have diabetic nephropathy or chronic kidney disease with proteinuria
• You have hypertension with documented LVH and want the stroke-reduction data from LIFE
• You are perimenopausal or postmenopausal and have newly elevated blood pressure
• You have PCOS with hypertension or microalbuminuria

Losartan Is Not Appropriate If:

• You are pregnant (absolute contraindication; see below)
• Your serum potassium is already above 5.0 mEq/L
• You are also taking an ACE inhibitor or the direct renin inhibitor aliskiren (combination increases risk of acute kidney injury and hyperkalemia)

Pregnancy, Lactation, and Contraception: A Required Section

Both drugs are contraindicated in pregnancy. This distinction is not a minor footnote. It is a clinical priority, especially for women in the reproductive years or perimenopause who may not yet be using reliable contraception.

Repatha (Evolocumab) in Pregnancy and Lactation

Evolocumab is classified as FDA Pregnancy Category not applicable under the current labeling system (post-2015 PLLR format), but the prescribing information states that human data are insufficient to establish fetal risk. Animal studies showed no evidence of fetal harm at exposures up to 12 times the human clinical dose, but animal data do not reliably predict human outcomes for monoclonal antibodies, which actively cross the placenta via FcRn receptors, particularly in the second and third trimesters.

The current recommendation is to avoid evolocumab during pregnancy. If you become pregnant while taking Repatha, stop the drug and contact your prescriber immediately.

Lactation data are absent. IgG1 antibodies are secreted into breast milk in small amounts, but neonatal intestinal absorption of large proteins is generally poor. Given the lack of data, most clinicians advise avoiding evolocumab during breastfeeding.

Women with familial hypercholesterolemia who are planning pregnancy face a particular challenge. Statins must be stopped before conception. Bile acid sequestrants (cholestyramine, colesevelam) are the only lipid-lowering agents with a reasonably reassuring pregnancy safety record, though they are pregnancy category B based on limited absorption data. Discuss a preconception lipid management plan with your clinician well in advance.

Losartan in Pregnancy and Lactation

Losartan is a well-documented teratogen. The drug blocks fetal angiotensin II signaling, which is essential for normal renal development. Exposure in the second or third trimester causes fetal renal tubular dysplasia, oligohydramnios, skull hypoplasia, limb contractures, and neonatal death. This risk is not theoretical. It is established across thousands of pregnancy exposures. The FDA issued a black box warning for this class (all ARBs and ACE inhibitors) decades ago.

If you are of reproductive age and taking losartan, reliable contraception is not optional. If you are trying to conceive or become unexpectedly pregnant, losartan must be stopped immediately and replaced with a pregnancy-safe antihypertensive. Safe alternatives include labetalol, nifedipine, and methyldopa, all of which have established human pregnancy safety data.

Losartan passes into breast milk in animal studies. Human lactation data are limited. Most guidelines recommend avoiding ARBs in breastfeeding mothers if alternatives are available. The NIH LactMed database rates losartan as probably not safe in nursing, preferring agents with more strong breastfeeding safety data such as nifedipine or captopril.

Side Effects and Tolerability Across Female Physiology

Women report adverse drug effects more frequently than men across most drug classes, a pattern driven by body composition differences, hormonal modulation of drug metabolism, and historically under-studied sex-disaggregated safety data.

Repatha Side Effects in Women

The most common side effects in FOURIER were nasopharyngitis, upper respiratory tract infection, influenza, and injection-site reactions. These were similar in frequency between evolocumab and placebo arms. Muscle pain (myalgia) was reported in roughly 5 percent of participants, though evolocumab itself does not cause myopathy in the way statins do. If you are experiencing myalgia on Repatha, consider whether your concomitant statin dose is the more likely contributor.

Women on evolocumab who are also on oral contraceptives or hormone therapy should know that no clinically meaningful drug-drug interaction has been identified between monoclonal antibody biologics and hormonal medications. PCSK9 inhibitors are not metabolized by CYP450 enzymes, so they do not compete for the same metabolic pathways as estrogen or progestins.

Losartan Side Effects in Women

Losartan's most common side effects are dizziness, hypotension (particularly on first dose or after dose increases), hyperkalemia, and elevated creatinine from reduced glomerular filtration pressure. Women who develop hyperkalemia on losartan may be at higher risk if they also take potassium-sparing diuretics, trimethoprim, or high-dose NSAIDs.

ACE inhibitors cause a dry cough in up to 15 percent of patients; losartan, as an ARB, causes cough far less frequently because it does not affect bradykinin metabolism. This is one reason ARBs are often preferred for women who have switched from ACE inhibitors due to cough intolerance.

Cost, Access, and Practical Considerations

Repatha carries a list price above $600 per month in the United States. Amgen offers a patient assistance program and a $5/month copay card for commercially insured patients. Prior authorization requirements are extensive: most insurers require documented LDL above 70 mg/dL despite maximally tolerated statin therapy plus evidence of ASCVD or FH.

Losartan is one of the most affordable cardiometabolic medications available. Generic losartan costs $10 to $25 for a 90-day supply at most pharmacies. It requires no prior authorization. Access barriers are minimal.

For a woman navigating both elevated LDL and hypertension, the question is not which drug to pick. Your clinician may prescribe both. The framing of "Repatha vs losartan" makes sense primarily if you have one condition (high LDL or high blood pressure) and are asking whether you need the targeted treatment or something else.

Monitoring and Follow-Up by Life Stage

Reproductive Years (18-40)

If you are taking losartan, your clinician should confirm you are using reliable contraception at every visit. A repeat basic metabolic panel checking potassium and creatinine should be drawn two to four weeks after starting or changing your dose. Blood pressure goals in this age group are below 130/80 mmHg.

If you are starting Repatha, a fasting lipid panel at four to twelve weeks confirms the LDL response. Injection-site reactions can be reduced by allowing the auto-injector to reach room temperature for 30 minutes before use.

Perimenopause (40-55 Approximate)

This is the window where LDL and blood pressure both tend to rise. Your clinician should recalculate your 10-year ASCVD risk using the Pooled Cohort Equations annually, as your risk category may shift without any change in lifestyle. Women who were previously at low risk may cross the threshold for statin initiation, and some will need PCSK9 inhibitor therapy added if LDL remains high despite a moderate-to-high intensity statin.

Bone health and cardiovascular health intersect here. Osteoporosis medications and cardiometabolic medications are not mutually exclusive, but be sure your clinician has a complete medication list to check for interactions, particularly if you are also on hormone therapy.

Postmenopause (55 and Beyond)

Cardiovascular disease is the leading cause of death in postmenopausal women in the United States. The American Heart Association estimates that nearly half of U.S. Women over 60 have some form of cardiovascular disease. Both elevated LDL and uncontrolled hypertension are major modifiable contributors. Women in this group are the most likely to benefit from evolocumab if they have established ASCVD and residual LDL risk on statin therapy, and from losartan or another ARB if hypertension is a separate or co-occurring problem.

Can You Take Both?

Yes. There is no interaction between evolocumab and losartan. They work on completely different biological pathways. A postmenopausal woman with prior MI, LDL of 85 mg/dL on rosuvastatin 40 mg, and blood pressure of 148/90 mmHg would be a reasonable candidate for both drugs simultaneously.

The clinical decision should be driven by which problem is most out of control and which target organ is most at risk. Elevated LDL in established ASCVD drives the decision toward Repatha. Sustained elevated blood pressure with kidney involvement or LVH drives the decision toward an ARB like losartan.

When to Ask About Switching or Adding

Contact your clinician promptly if:

• Your LDL remains above 70 mg/dL (established ASCVD) or above 100 mg/dL (primary prevention) despite a high-intensity statin; your clinician may discuss adding evolocumab
• Your blood pressure readings at home consistently exceed 135/85 mmHg; your clinician may discuss adding or titrating losartan
• You develop new symptoms of muscle pain, weakness, or dark urine on your current statin; this warrants reassessment before any PCSK9 inhibitor is added
• You are planning a pregnancy within the next 12 months and are currently on losartan; transition planning should begin immediately

Your next LDL panel should be drawn fasting, in the early follicular phase if you still have cycles, and four to twelve weeks after any change to lipid-lowering therapy.